GQ-1010 is under clinical development by Biohaven and currently in Phase II for Epithelial Tumor. According to GlobalData, Phase II drugs for Epithelial Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GQ-1010 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GQ-1010 overview
GQ-1010 is under development for the treatment of solid tumors including non-small cell lung cancer, gastroesophageal junction cancer, breast cancer triple-negative breast cancer, colorectal cancer, cholangiocarcinoma, pancreatic cancer, endometrial cancer, ovarian cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), cervical cancer, head and neck squamous cell carcinoma and advanced epithelial tumors. It is a first-in class drug candidate and is being developed based on Ligase Dependent Conjugation (LDC) technology. It is administered through intravenous route. It acts by targeting targeting cells expressing tumor associated calcium signal transducer 2 (Trop 2).
Biohaven overview
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of GQ-1010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
